JP2020158521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020158521A5 JP2020158521A5 JP2020103455A JP2020103455A JP2020158521A5 JP 2020158521 A5 JP2020158521 A5 JP 2020158521A5 JP 2020103455 A JP2020103455 A JP 2020103455A JP 2020103455 A JP2020103455 A JP 2020103455A JP 2020158521 A5 JP2020158521 A5 JP 2020158521A5
- Authority
- JP
- Japan
- Prior art keywords
- collagenase
- pharmaceutical composition
- composition according
- administered
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 102000029816 Collagenase Human genes 0.000 claims 15
- 108060005980 Collagenase Proteins 0.000 claims 15
- 229960002424 collagenase Drugs 0.000 claims 15
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims 14
- 238000010254 subcutaneous injection Methods 0.000 claims 12
- 239000007929 subcutaneous injection Substances 0.000 claims 12
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000193159 Hathewaya histolytica Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022098817A JP2022123073A (ja) | 2011-10-21 | 2022-06-20 | Ｅｆｐの治療または低減方法 |
| JP2024098658A JP2024123126A (ja) | 2011-10-21 | 2024-06-19 | Ｅｆｐの治療または低減方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549863P | 2011-10-21 | 2011-10-21 | |
| US61/549,863 | 2011-10-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017183076A Division JP2018027968A (ja) | 2011-10-21 | 2017-09-22 | Ｅｆｐの治療または低減方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022098817A Division JP2022123073A (ja) | 2011-10-21 | 2022-06-20 | Ｅｆｐの治療または低減方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020158521A JP2020158521A (ja) | 2020-10-01 |
| JP2020158521A5 true JP2020158521A5 (enExample) | 2020-12-17 |
Family
ID=48141393
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537297A Pending JP2014530873A (ja) | 2011-10-21 | 2012-10-19 | Ｅｆｐの治療または低減方法 |
| JP2017183076A Pending JP2018027968A (ja) | 2011-10-21 | 2017-09-22 | Ｅｆｐの治療または低減方法 |
| JP2020103455A Pending JP2020158521A (ja) | 2011-10-21 | 2020-06-16 | Ｅｆｐの治療または低減方法 |
| JP2022098817A Pending JP2022123073A (ja) | 2011-10-21 | 2022-06-20 | Ｅｆｐの治療または低減方法 |
| JP2024098658A Pending JP2024123126A (ja) | 2011-10-21 | 2024-06-19 | Ｅｆｐの治療または低減方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537297A Pending JP2014530873A (ja) | 2011-10-21 | 2012-10-19 | Ｅｆｐの治療または低減方法 |
| JP2017183076A Pending JP2018027968A (ja) | 2011-10-21 | 2017-09-22 | Ｅｆｐの治療または低減方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022098817A Pending JP2022123073A (ja) | 2011-10-21 | 2022-06-20 | Ｅｆｐの治療または低減方法 |
| JP2024098658A Pending JP2024123126A (ja) | 2011-10-21 | 2024-06-19 | Ｅｆｐの治療または低減方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140335072A1 (enExample) |
| EP (2) | EP2768523B1 (enExample) |
| JP (5) | JP2014530873A (enExample) |
| AU (6) | AU2012325941A1 (enExample) |
| BR (1) | BR112014009785B1 (enExample) |
| CA (1) | CA2852942C (enExample) |
| DK (2) | DK2768523T3 (enExample) |
| ES (2) | ES2953560T3 (enExample) |
| FI (1) | FI3581199T3 (enExample) |
| HU (2) | HUE044650T2 (enExample) |
| MX (2) | MX2014004792A (enExample) |
| PL (1) | PL3581199T3 (enExample) |
| PT (2) | PT3581199T (enExample) |
| WO (1) | WO2013059619A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4015627B1 (en) | 2012-01-12 | 2023-09-27 | Endo Global Ventures | Clostridium histolyticum enzyme |
| CN104271152B (zh) | 2012-05-01 | 2016-08-17 | 普罗泰奥里斯有限公司 | 拔出牙齿的方法 |
| US9744138B2 (en) | 2013-03-15 | 2017-08-29 | Biospecifics Technologies Corp. | Treatment method and product for uterine fibroids using purified collagenase |
| CN103751102A (zh) * | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| EP4591945A2 (en) | 2017-03-01 | 2025-07-30 | Endo Operations Limited | Apparatus and method for assessing and treating cellulite |
| US11473074B2 (en) * | 2017-03-28 | 2022-10-18 | Endo Global Aesthetics Limited | Method of producing collagenase |
| WO2020021332A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| WO2020021330A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| MX2021000901A (es) * | 2018-07-23 | 2021-06-18 | Revelle Aesthetics Inc | Sistema y metodos de tratamiento de celulitis. |
| AU2019341663C1 (en) * | 2018-09-18 | 2025-08-07 | Endo Global Aesthetics Limited | Compositions and methods for treating cellulite |
| WO2020142701A1 (en) * | 2019-01-06 | 2020-07-09 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
| US11872267B2 (en) | 2019-10-15 | 2024-01-16 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
| EP3861948A1 (en) * | 2020-02-10 | 2021-08-11 | Daniel A. Del Vecchio | Cellulite eradication methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| US4524065A (en) * | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
| US6958150B2 (en) * | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| EP3424508B1 (en) * | 2004-05-19 | 2021-05-05 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Use of sodium deoxycholate for the removal of localized fat accumulation |
| US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| WO2007100590A2 (en) * | 2006-02-22 | 2007-09-07 | Auxilium Pharmaceuticals, Inc. | Methods for treating cellulite |
| CN102784387A (zh) * | 2007-02-14 | 2012-11-21 | 友莱尔皮肤产品有限责任公司 | 修饰的突变体胶原蛋白酶及其在脂肪溶解和疤痕减少中的应用 |
-
2012
- 2012-10-19 CA CA2852942A patent/CA2852942C/en active Active
- 2012-10-19 BR BR112014009785-2A patent/BR112014009785B1/pt active IP Right Grant
- 2012-10-19 FI FIEP19172643.9T patent/FI3581199T3/fi active
- 2012-10-19 ES ES19172643T patent/ES2953560T3/es active Active
- 2012-10-19 HU HUE12842537 patent/HUE044650T2/hu unknown
- 2012-10-19 ES ES12842537T patent/ES2741476T3/es active Active
- 2012-10-19 HU HUE19172643A patent/HUE063599T2/hu unknown
- 2012-10-19 WO PCT/US2012/061063 patent/WO2013059619A1/en not_active Ceased
- 2012-10-19 PT PT191726439T patent/PT3581199T/pt unknown
- 2012-10-19 DK DK12842537.8T patent/DK2768523T3/da active
- 2012-10-19 JP JP2014537297A patent/JP2014530873A/ja active Pending
- 2012-10-19 EP EP12842537.8A patent/EP2768523B1/en active Active
- 2012-10-19 PL PL19172643.9T patent/PL3581199T3/pl unknown
- 2012-10-19 AU AU2012325941A patent/AU2012325941A1/en not_active Abandoned
- 2012-10-19 DK DK19172643.9T patent/DK3581199T3/da active
- 2012-10-19 PT PT12842537T patent/PT2768523T/pt unknown
- 2012-10-19 MX MX2014004792A patent/MX2014004792A/es active IP Right Grant
- 2012-10-19 MX MX2019007779A patent/MX392388B/es unknown
- 2012-10-19 EP EP19172643.9A patent/EP3581199B1/en active Active
-
2014
- 2014-04-17 US US14/255,407 patent/US20140335072A1/en not_active Abandoned
-
2016
- 2016-03-31 AU AU2016202026A patent/AU2016202026A1/en not_active Abandoned
-
2017
- 2017-09-22 JP JP2017183076A patent/JP2018027968A/ja active Pending
- 2017-10-17 AU AU2017248451A patent/AU2017248451B2/en active Active
-
2020
- 2020-02-03 AU AU2020200763A patent/AU2020200763B2/en active Active
- 2020-06-16 JP JP2020103455A patent/JP2020158521A/ja active Pending
-
2022
- 2022-05-04 AU AU2022202987A patent/AU2022202987B2/en active Active
- 2022-06-20 JP JP2022098817A patent/JP2022123073A/ja active Pending
-
2024
- 2024-01-17 US US18/415,270 patent/US20240216485A1/en not_active Abandoned
- 2024-06-19 JP JP2024098658A patent/JP2024123126A/ja active Pending
-
2025
- 2025-06-16 AU AU2025204462A patent/AU2025204462A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020158521A5 (enExample) | ||
| Kendrick et al. | Rhabdomyolysis and shock after intravenous amphetamine administration | |
| CN1917883B (zh) | 曲前列环素在制备改善肾功能的药物中的用途 | |
| JP2024123126A (ja) | Ｅｆｐの治療または低減方法 | |
| JP2014530873A5 (enExample) | ||
| JP2016204396A5 (enExample) | ||
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| HRP20151182T1 (hr) | Kolagenaza za tretiranje celulita | |
| EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| EP0491018A1 (en) | Use of taurolidine and/or taurultam for the treatment of tumours | |
| EP0455725B1 (en) | Pharmaceutical formulations of plasminogen activator proteins | |
| RU2008121874A (ru) | Стабильные фармацевтические составы, которые содержат интерфероны гамма и альфа в синергичных соотношениях | |
| CN110433160A (zh) | 一种治疗肝纤维化的化合物及其应用 | |
| US20110183926A1 (en) | Treatment using continuous low dose application of sugar analogs | |
| EP3636265A1 (en) | Application of nicotinamide composition in preparing drug for treating sorafenib-induced hand-foot skin reaction | |
| AU630373B2 (en) | Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination | |
| JPS6150927B2 (enExample) | ||
| US20040057947A1 (en) | Drug combinations based on magnesium salts and fibrinolytics | |
| CA2491712A1 (en) | New drug combinations based on magnesium salts and fibrinolytics | |
| EP0648125A1 (en) | Anti-inflammatory agent | |
| JPWO2020197967A5 (enExample) | ||
| WO2025195268A1 (zh) | 药物组合物在治疗糖尿病周围神经病变上的应用 | |
| JPH0242027A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
| Dishy et al. | Reversal of the Anticoagulant Effect of Milvexian By 4-Factor PCC and rFVIIa in Healthy Participants | |
| WO2021129779A1 (zh) | 一种新型两亲性蛋白、其制备方法及用途 |